4.8 Article

Mitoquinone Inactivates Mitochondrial Chaperone TRAP1 by Blocking the Client Binding Site

期刊

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
卷 143, 期 47, 页码 19684-19696

出版社

AMER CHEMICAL SOC
DOI: 10.1021/jacs.1c07099

关键词

-

资金

  1. National Research Foundation of Korea - Korea government (MSIT) [NRF-2019R1A2C2086618, NRF-2018R1A5A1024340, NRF-2021R1A2C2009550, NRF-2021M3A9G8022413]
  2. Tech Incubator Program for Startup Korea (TIPS) program - Korea government (MSS) [S2783310]
  3. Institute for Basic Science grant [IBS-R022-D1]
  4. Korea Technology & Information Promotion Agency for SMEs (TIPA) [S2783310] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

The study identified Mitoquinone (MitoQ) as a potent inhibitor of mitochondrial Hsp90, offering potential anticancer properties. By competitively binding with TRAP1 clients, MitoQ facilitated the identification of mitochondrial protein interactions. Targeting the client binding site of Hsp90 family proteins provides a novel strategy for developing potent anticancer drugs.
Heat shock protein 90 (Hsp90) family proteins are molecular chaperones that modulate the functions of various substrate proteins (clients) implicated in pro-tumorigenic pathways. In this study, the mitochondria-targeted antioxidant mitoquinone (MitoQ) was identified as a potent inhibitor of mitochondrial Hsp90, known as a tumor necrosis factor receptor-associated protein 1 (TRAP1). Structural analyses revealed an asymmetric bipartite interaction between MitoQ and the previously unrecognized drug binding sites located in the middle domain of TRAP1, believed to be a client binding region. MitoQ effectively competed with TRAP1 clients, and MitoQ treatment facilitated the identification of 103 TRAP1-interacting mitochondrial proteins in cancer cells. MitoQ and its redox-crippled SB-U014/SB-U015 exhibited more potent anticancer activity in vitro and in vivo than previously reported mitochondria-targeted TRAP1 inhibitors. The findings indicate that targeting the client binding site of Hsp90 family proteins offers a novel strategy for the development of potent anticancer drugs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据